Black Diamond's Unique Approach

Targeting Allosteric RTK Mutants

Black Diamond Therapeutics has developed a proprietary method to uncover and target allosteric mutant oncogenes.

Black Diamond Therapeutics is using its MAP platform to extend its approach to developing drugs to a range of high value oncogenic targets.

Pipeline Overview

Allosteric Mutations

A new class of genetically-defined driver mutations

→ Pharmacology uncovered by Black Diamond

→ Resistant to conventional, standard-of-care kinase inhibitors

→ Significant patient populations with high unmet need


Black Diamond’s MAP drug discovery platform mines and validates genetically-defined allosteric mutant oncogenes

Pipeline Targeting
Oncogenic Allosteric Mutants